Developer docs
API playgroundTry for free, no card

Search company profiles

Invenomic Capital Management

Full company profile

uuid000noc2

Namestring
Invenomic Capital Management
Legal namestring
Invenomic Capital Management, LP
Websiteurl
invenomic.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long short equity, investment management, asset management, alternative investments, mutual fund management
Industry1 code
PRIMARYFSAAAEAA
Equity Mutual Funds (Active)
Financial & Insurance/Asset & Wealth Management/Asset Management — Mutual Funds & UCITS
NAICS code2 codes
  • Open-End Investment Funds525910
  • Open-End Investment Funds52591
SIC code1 code
  • Investment Advice6282
Product category
Long/Short Equity Mutual Fund
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management Fees
TypeSubscription Recurring
Description

The fund charges management fees through tiered expense ratios for different share classes: Institutional Class (2.23% net), Investor Class (2.48% net), Super Institutional Class (1.98% net). Redemption fee of 1.00% on shares sold within 60 days. Gross expense ratios range from 2.82% to 3.32% depending on share class.

invenomic.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details3 tiers
1Institutional Class shares with 2.23% net expense ratio
ModelSubscriptionBilling cadenceAnnual
Notes

Net expense ratio: 2.23% (through Feb 28, 2027). Gross expense ratio: 3.07%. Redemption fee: 1.00% on shares sold within 60 days.

invenomic.com
2Investor Class shares with 2.48% net expense ratio
ModelSubscriptionBilling cadenceAnnual
Notes

Net expense ratio: 2.48% (through Feb 28, 2027). Gross expense ratio: 3.32%. Redemption fee: 1.00% on shares sold within 60 days.

invenomic.com
3Super Institutional Class shares with 1.98% net expense ratio
ModelSubscriptionBilling cadenceAnnual
Notes

Net expense ratio: 1.98% (through Feb 28, 2027). Gross expense ratio: 2.82%. Redemption fee: 1.00% on shares sold within 60 days.

invenomic.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Invenomic Capital Management manages The Invenomic Fund, a long/short equity mutual fund that invests primarily in U.S. equities using a hybrid process combining quantitative idea sourcing with traditional fundamental analysis. The fund is offered in three share classes (Institutional, Investor, Super Institutional) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is distributed by Northern Lights Distributors, LLC to U.S. institutional and high-net-worth investors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Long portfolio typically 90%+ invested during most market environments
+1 more record
Product overview1 text field

Invenomic Capital Management operates as a single unified investment product: The Invenomic Fund. The fund is a long/short equity strategy that combines quantitative analysis on the front end to source ideas with traditional fundamental analysis to construct a portfolio of long and short equity positions. The fund offers three share class variants (Institutional Class, Investor Class, and Super Institutional Class) that differ primarily in fee structures and minimum investment requirements, with fund inception dated June 19, 2017.

Product and service1 record
1The Invenomic Fund
CategoryLong/Short Equity Mutual Fund
Description

A long/short equity mutual fund that employs a disciplined, fundamentally-driven research process to build a diversified portfolio of primarily U.S. focused long and short equity investments. The fund is offered in three share classes (Institutional BIVSX, Investor BIVRX, and Super Institutional BIVIX) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is managed by Portfolio Manager Ali Motamed for U.S. institutional and accredited/high-net-worth investors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Northern Lights Distributors, LLC is the fund distributor for The Invenomic Fund. They are a FINRA member broker-dealer (member FINRA/SIPC) responsible for distributing the fund shares to investors in the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based alternatives manager running marketable securities portfolios. Brendan Dougherty worked in operations there prior to Invenomic, and the firm represents a similar-sized Boston alternatives boutique.

2Gabelli Funds (Mario Gabelli)
TypeBroad incumbent
Description

Long-running, fundamental-driven U.S. equity manager with mutual fund and institutional offerings. Comparable on long-only and hedged U.S. equity mutual fund distribution and fundamental research approach.

TypeBroad incumbent
Description

Large, established quantitative asset manager with a flagship long/short equity fund. Competitor for institutional long/short equity mandates at scale, with a much broader product suite and deeper quant research infrastructure.

TypeBroad incumbent
Description

Established alternatives manager with multiple long/short and market-neutral mutual fund products. Competes for the same U.S. mutual fund-distributed long/short equity allocator.

TypeDirect peer
Description

Long/short equity manager where Invenomic's founder Ali Motamed previously co-ran the Long/Short Equity Fund. Direct comparable on strategy, U.S. focus, and institutional client base.

TypeDirect peer
Description

Hedged U.S. equity mutual fund manager emphasizing risk management and downside protection. Directly comparable on mutual-fund distribution of a hedged U.S. equity strategy for retail and institutional investors.

7Balter Liquid Alternatives
TypeDirect peer
Description

Long/short equity mutual fund manager with a U.S. focus, founded by Nazar Massouh. Multiple Invenomic executives (President Ben Deschaine, Head of Client Relationships Bob Marx, and Client Relationship Kevin Ross) came directly from Balter, making it the closest comparable in product, channel, and talent pedigree.

TypeDirect peer
Description

Quantitative, fundamentally-driven U.S. equity manager operating a small-cap value strategy. Brendan Dougherty (Invenomic's Director of Operations) spent over a decade at Bogle, making it a close operational and stylistic peer.

9The Merger Fund (Mercer Advisors)
TypeDirect peer
Description

Long-running, mutual-fund-structured alternative strategy focused on event-driven U.S. equity. Comparable on offering a hedge-fund-style strategy through a U.S. mutual fund wrapper to retail and institutional clients.

TypeDirect peer
Description

Activist-leaning, fundamentally-driven U.S. long/short equity manager. Comparable on the focus on financial statement analysis, U.S. mandate, and concentrated fundamental research process.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invenomic Capital Management

Long/Short Equity Mutual Fundinvenomic.com

Invenomic Capital Management firmographics

Firmographics
Name
Invenomic Capital Management
Legal name
Invenomic Capital Management, LP
Website
https://invenomic.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Invenomic Capital Management industry classification

Industry
Product category
Long/Short Equity Mutual Fund
NAICS
Open-End Investment Funds (525910), Open-End Investment Funds (52591)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAAAEAA
Equity Mutual Funds (Active)
Financial & Insurance/Asset & Wealth Management/Asset Management — Mutual Funds & UCITS

Keywords

  • Long short equity
  • Investment management
  • Asset management
  • Alternative investments
  • Mutual fund management

Where Invenomic Capital Management is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Invenomic Capital Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Investment Management Fees: The fund charges management fees through tiered expense ratios for different share classes: Institutional Class (2.23% net), Investor Class (2.48% net), Super Institutional Class (1.98% net). Redemption fee of 1.00% on shares sold within 60 days. Gross expense ratios range from 2.82% to 3.32% depending on share class.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualInstitutional Class shares with 2.23% net expense ratio
SubscriptionAnnualInvestor Class shares with 2.48% net expense ratio
SubscriptionAnnualSuper Institutional Class shares with 1.98% net expense ratio

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Invenomic Capital Management product offering

Product offering

Core offering

Invenomic Capital Management manages The Invenomic Fund, a long/short equity mutual fund that invests primarily in U.S. equities using a hybrid process combining quantitative idea sourcing with traditional fundamental analysis. The fund is offered in three share classes (Institutional, Investor, Super Institutional) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is distributed by Northern Lights Distributors, LLC to U.S. institutional and high-net-worth investors.

Product overview

Invenomic Capital Management operates as a single unified investment product: The Invenomic Fund. The fund is a long/short equity strategy that combines quantitative analysis on the front end to source ideas with traditional fundamental analysis to construct a portfolio of long and short equity positions. The fund offers three share class variants (Institutional Class, Investor Class, and Super Institutional Class) that differ primarily in fee structures and minimum investment requirements, with fund inception dated June 19, 2017.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Invenomic Fund A long/short equity mutual fund that employs a disciplined, fundamentally-driven research process to build a diversified portfolio of primarily U.S. focused long and short equity investments. The fund is offered in three share classes (Institutional BIVSX, Investor BIVRX, and Super Institutional BIVIX) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is managed by Portfolio Manager Ali Motamed for U.S. institutional and accredited/high-net-worth investors.

Quantifiable outcome

  • Long portfolio typically 90%+ invested during most market environments
  • +1 more outcomes

Companies that use Invenomic Capital Management

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Invenomic Capital Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Invenomic Capital Management partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Northern Lights Distributors, LLCcoreChannel Partner/ Reseller/ DistributorNorthern Lights Distributors, LLC is the fund distributor for The Invenomic Fund. They are a FINRA member broker-dealer (member FINRA/SIPC) responsible for distributing the fund shares to investors in the United States.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Invenomic Capital Management competitors and assessment

Company assessment

Direct peers

  • HighVista Strategies: Boston-based alternatives manager running marketable securities portfolios. Brendan Dougherty worked in operations there prior to Invenomic, and the firm represents a similar-sized Boston alternatives boutique.
  • Boston Partners: Long/short equity manager where Invenomic's founder Ali Motamed previously co-ran the Long/Short Equity Fund. Direct comparable on strategy, U.S. focus, and institutional client base.
  • Hussman Strategic Advisors: Hedged U.S. equity mutual fund manager emphasizing risk management and downside protection. Directly comparable on mutual-fund distribution of a hedged U.S. equity strategy for retail and institutional investors.
  • Balter Liquid Alternatives: Long/short equity mutual fund manager with a U.S. focus, founded by Nazar Massouh. Multiple Invenomic executives (President Ben Deschaine, Head of Client Relationships Bob Marx, and Client Relationship Kevin Ross) came directly from Balter, making it the closest comparable in product, channel, and talent pedigree.
  • Bogle Investment Management: Quantitative, fundamentally-driven U.S. equity manager operating a small-cap value strategy. Brendan Dougherty (Invenomic's Director of Operations) spent over a decade at Bogle, making it a close operational and stylistic peer.
  • The Merger Fund (Mercer Advisors): Long-running, mutual-fund-structured alternative strategy focused on event-driven U.S. equity. Comparable on offering a hedge-fund-style strategy through a U.S. mutual fund wrapper to retail and institutional clients.
  • ValueAct Capital: Activist-leaning, fundamentally-driven U.S. long/short equity manager. Comparable on the focus on financial statement analysis, U.S. mandate, and concentrated fundamental research process.

Broad incumbents

  • Gabelli Funds (Mario Gabelli): Long-running, fundamental-driven U.S. equity manager with mutual fund and institutional offerings. Comparable on long-only and hedged U.S. equity mutual fund distribution and fundamental research approach.
  • AQR Capital Management: Large, established quantitative asset manager with a flagship long/short equity fund. Competitor for institutional long/short equity mandates at scale, with a much broader product suite and deeper quant research infrastructure.
  • Calamos Investments: Established alternatives manager with multiple long/short and market-neutral mutual fund products. Competes for the same U.S. mutual fund-distributed long/short equity allocator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Invenomic Capital Management social profiles

Digital presence

Invenomic Capital Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invenomic Capital Management leadership team

Management profile

Number of profiles

Profiles7 records

Invenomic Capital Management funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invenomic Capital Management M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invenomic Capital Management

What does Invenomic Capital Management do?

Invenomic Capital Management manages The Invenomic Fund, a long/short equity mutual fund that invests primarily in U.S. equities using a hybrid process combining quantitative idea sourcing with traditional fundamental analysis. The fund is offered in three share classes (Institutional, Investor, Super Institutional) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is distributed by Northern Lights Distributors, LLC to U.S. institutional and high-net-worth investors.

Is Invenomic Capital Management a public or private company?

Invenomic Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Invenomic Capital Management founded?

Invenomic Capital Management was founded in 2017. It employs 11 to 50 people.

Where is Invenomic Capital Management based?

Invenomic Capital Management is headquartered in Boston, United States, in the North America region.

How does Invenomic Capital Management make money?

One revenue line is on record: investment Management Fees.

Who are Invenomic Capital Management's main competitors?

Direct peers on record are HighVista Strategies, Boston Partners, Hussman Strategic Advisors, Balter Liquid Alternatives, Bogle Investment Management, The Merger Fund (Mercer Advisors) and ValueAct Capital. Broad incumbents are Gabelli Funds (Mario Gabelli), AQR Capital Management and Calamos Investments.

Does Invenomic Capital Management have an API?

No public API is recorded for Invenomic Capital Management.

What industry is Invenomic Capital Management in?

Invenomic Capital Management's product category is Long/Short Equity Mutual Fund. Its primary akta.pro industry code is FSAAAEAA, Equity Mutual Funds (Active). Its NAICS code is 525910 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TIKRA $3.4 Billion Fund Dumps These 2 StocksInvenomic Capital Management sold all its Becton Dickinson and BILL shares in Q3, per its 13F. BILL agreed to a $63.25-a-share cash buyout, while Amentum and GoDaddy have higher analyst upside. The fund's next 13F is due by mid-February.MarketBeatInvenomic Capital Management LP Sells 750,958 Shares of RLJ Lodging Trust $RLJInvenomic Capital Management LP sold 750,958 shares of RLJ Lodging Trust in Q1, reducing its stake by 84.9% to 134,070 shares. RLJ reported Q2 EPS of $0.48, beating estimates, and paid a $0.15 quarterly dividend. Analysts rate the stock a Hold with a $9.50 average target.MarketBeatInvenomic Capital Management LP Buys New Holdings in Warner Bros. Discovery, Inc. $WBDInvenomic Capital Management LP acquired a new stake in Warner Bros. Discovery, buying 3,254,123 shares worth about $34.9 million in Q1. The stake represents 0.13% of the company, and analysts have a consensus 'Moderate Buy' rating with an average target price of $13.14.MarketBeatInvenomic Capital Management LP Has $49.35 Million Position in Global Payments Inc. $GPNInvenomic Capital Management LP trimmed its Global Payments stake by 5.9% in Q1, selling 31,488 shares and holding 503,966 shares worth $49.35 million. The stock opened at $87.23, and analysts rate it a Hold with a consensus price target of $112.21.MarketBeatIntel Co. (NASDAQ:INTC) Shares Purchased by Invenomic Capital Management LPInvenomic Capital Management LP raised its Intel stake by 79.7% in Q4, buying 183,216 shares to hold 413,151 shares worth $8.28 million. Other funds also increased positions, and analysts rate Intel a Hold with an average target of $21.67.MarketBeatInvenomic Capital Management LP Reduces Stake in Enterprise Products Partners L.P. (NYSE:EPD)Invenomic Capital Management LP cut its Enterprise Products Partners stake by 55.8% in Q3, selling 153,033 shares and holding 121,441 shares worth $3.535 million. Other funds like Tortoise, FMR, and Pathway increased positions, while analysts rate the stock a Buy with a $34 average target.MarketBeatInvenomic Capital Management LP Increases Position in 3M (NYSE:MMM)Invenomic Capital Management LP increased its 3M stake by 153.3% in Q1, holding 392,623 shares worth $41.6 million. The stock is 2.2% of Invenomic's portfolio and 65.25% of 3M is institutionally owned. Analysts rate 3M a 'Hold' with an average target of $123.57.Business InsiderThe managers of a high-flying value fund that's crushing the market and beating 99% of its competition this year told us how they're doing it — and the vital role that betting against stocks plays inInvenomic Capital Management's Balter Invenomic Fund returned 38.3% as of July 12, nearly quadruple the long-short category's 9.9% and double the S&P 500. The fund holds about 160 long and 180 short positions, with shorts used as a second return method. The fund has returned 95% since its June 2017 inception.